Glaxo Says Promacta for Hepatitis C Cured Patients in Trial

GlaxoSmithKline Plc said its Promacta blood disorder medicine eradicated hepatitis C in 23 percent of patients in a clinical trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.